Which has higher valuation and earnings, IMMX or AARD?

Immix Biopharma is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is IMMX or AARD more profitable?

Aardvark Therapeutics' return on equity of -61.71% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media refer more to IMMX or AARD?

In the previous week, Aardvark Therapeutics had 13 more articles in the media than Immix Biopharma. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 7 mentions for Immix Biopharma. Aardvark Therapeutics' average media sentiment score of 0.48 beat Immix Biopharma's score of 0.20 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STTK or AARD more profitable?

Shattuck Labs' return on equity of -60.73% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media prefer STTK or AARD?

In the previous week, Aardvark Therapeutics had 9 more articles in the media than Shattuck Labs. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 11 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.69 beat Aardvark Therapeutics' score of 0.48 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AARD or DNA?

In the previous week, Aardvark Therapeutics had 19 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 1 mentions for Ginkgo Bioworks. Aardvark Therapeutics' average media sentiment score of 0.48 beat Ginkgo Bioworks' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, EIKN or AARD?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A -$2.46 N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is EIKN or AARD more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Aardvark Therapeutics N/A -61.71% -56.29%

Does the media favor EIKN or AARD?

In the previous week, Aardvark Therapeutics had 17 more articles in the media than Eikon Therapeutics. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 3 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.62 beat Aardvark Therapeutics' score of 0.48 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CTNM or AARD more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -27.09% -25.64% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media prefer CTNM or AARD?

In the previous week, Aardvark Therapeutics had 15 more articles in the media than Contineum Therapeutics. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 5 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.93 beat Aardvark Therapeutics' score of 0.48 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Aardvark Therapeutics (AARD) Competitors

$6.32 -0.07 (-1.10%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$6.30 -0.02 (-0.32%)

As of 07/24/2026 07:34 PM Eastern

Compare

AARD vs. IMMX, STTK, DNA, EIKN, and CTNM

Should you buy Aardvark Therapeutics stock or one of its competitors? MarketBeat compares Aardvark Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aardvark Therapeutics include Immix Biopharma (IMMX), Shattuck Labs (STTK), Ginkgo Bioworks (DNA), Eikon Therapeutics (EIKN), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.

How does Aardvark Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Immix Biopharma currently has a consensus price target of $20.71, suggesting a potential upside of 143.13%. Aardvark Therapeutics has a consensus price target of $16.30, suggesting a potential upside of 157.91%. Given Aardvark Therapeutics' higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

In the previous week, Aardvark Therapeutics had 13 more articles in the media than Immix Biopharma. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 7 mentions for Immix Biopharma. Aardvark Therapeutics' average media sentiment score of 0.48 beat Immix Biopharma's score of 0.20 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.3% of Immix Biopharma shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immix Biopharma has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.93, indicating that its share price is 293% more volatile than the broader market.

Immix Biopharma is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Aardvark Therapeutics' return on equity of -61.71% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Summary

Aardvark Therapeutics beats Immix Biopharma on 8 of the 14 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Shattuck Labs has higher revenue and earnings than Aardvark Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	569.74	-$48.81M	-$0.63	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Shattuck Labs has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.93, suggesting that its stock price is 293% more volatile than the broader market.

Shattuck Labs' return on equity of -60.73% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Aardvark Therapeutics had 9 more articles in the media than Shattuck Labs. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 11 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.69 beat Aardvark Therapeutics' score of 0.48 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shattuck Labs currently has a consensus target price of $12.63, suggesting a potential upside of 69.92%. Aardvark Therapeutics has a consensus target price of $16.30, suggesting a potential upside of 157.91%. Given Aardvark Therapeutics' higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Summary

Shattuck Labs beats Aardvark Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Ginkgo Bioworks?

Aardvark Therapeutics (NASDAQ:AARD) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Aardvark Therapeutics currently has a consensus target price of $16.30, indicating a potential upside of 157.91%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential upside of 15.47%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aardvark Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aardvark Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Aardvark Therapeutics has a beta of 3.93, suggesting that its share price is 293% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 19 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 1 mentions for Ginkgo Bioworks. Aardvark Therapeutics' average media sentiment score of 0.48 beat Ginkgo Bioworks' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aardvark Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Ginkgo Bioworks	$151.40M	3.18	-$312.76M	-$5.36	N/A

Summary

Aardvark Therapeutics beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Eikon Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

In the previous week, Aardvark Therapeutics had 17 more articles in the media than Eikon Therapeutics. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 3 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.62 beat Aardvark Therapeutics' score of 0.48 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eikon Therapeutics currently has a consensus target price of $25.20, indicating a potential upside of 183.15%. Aardvark Therapeutics has a consensus target price of $16.30, indicating a potential upside of 157.91%. Given Eikon Therapeutics' higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Summary

Eikon Therapeutics and Aardvark Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

In the previous week, Aardvark Therapeutics had 15 more articles in the media than Contineum Therapeutics. MarketBeat recorded 20 mentions for Aardvark Therapeutics and 5 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.93 beat Aardvark Therapeutics' score of 0.48 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Contineum Therapeutics' return on equity of -27.09% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Contineum Therapeutics currently has a consensus price target of $20.00, suggesting a potential upside of 42.25%. Aardvark Therapeutics has a consensus price target of $16.30, suggesting a potential upside of 157.91%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Aardvark Therapeutics has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	10.51	-$59.98M	-$1.95	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Contineum Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.93, indicating that its stock price is 293% more volatile than the broader market.

Summary

Aardvark Therapeutics beats Contineum Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AARD vs. The Competition

Export

Metric	Aardvark Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$138.31M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.97	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.29	7.88	10.28	6.07
Net Income	-$57.59M	$23.86M	$3.60B	$331.99M
7 Day Performance	7.85%	-3.82%	-1.27%	-0.63%
1 Month Performance	24.90%	-2.61%	-0.37%	-2.00%
1 Year Performance	-57.01%	32.79%	18.30%	13.62%

Aardvark Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AARD Aardvark Therapeutics	3.3181 of 5 stars	$6.32 -1.1%	$16.30 +157.9%	-53.1%	$138.31M	N/A	N/A	18	News Coverage Analyst Revision
IMMX Immix Biopharma	3.006 of 5 stars	$10.25 +1.9%	$20.67 +101.6%	+205.4%	$547.38M	N/A	N/A	9	News Coverage Analyst Forecast
STTK Shattuck Labs	3.072 of 5 stars	$7.53 +6.5%	$11.00 +46.1%	+754.9%	$542.13M	$1M	N/A	100	News Coverage Analyst Forecast
DNA Ginkgo Bioworks	1.3094 of 5 stars	$7.88 -4.9%	$8.50 +7.8%	-50.6%	$541.54M	$170.15M	N/A	640
EIKN Eikon Therapeutics	2.232 of 5 stars	$9.77 -1.8%	$25.20 +157.9%	N/A	$528.94M	N/A	N/A	384	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aardvark Therapeutics (AARD) Competitors

AARD vs. IMMX, STTK, DNA, EIKN, and CTNM

How does Aardvark Therapeutics compare to Immix Biopharma?

Summary

How does Aardvark Therapeutics compare to Shattuck Labs?

Summary

How does Aardvark Therapeutics compare to Ginkgo Bioworks?

Summary

How does Aardvark Therapeutics compare to Eikon Therapeutics?

Summary

How does Aardvark Therapeutics compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aardvark Therapeutics (AARD) Competitors

AARD vs. IMMX, STTK, DNA, EIKN, and CTNM

How does Aardvark Therapeutics compare to Immix Biopharma?

Do analysts prefer IMMX or AARD?

Does the media refer more to IMMX or AARD?

Do institutionals and insiders have more ownership in IMMX or AARD?

Which has more volatility & risk, IMMX or AARD?

Which has higher valuation and earnings, IMMX or AARD?

Is IMMX or AARD more profitable?

Summary

How does Aardvark Therapeutics compare to Shattuck Labs?

Which has preferable valuation and earnings, STTK or AARD?

Which has more risk and volatility, STTK or AARD?

Is STTK or AARD more profitable?

Do institutionals and insiders have more ownership in STTK or AARD?

Does the media prefer STTK or AARD?

Do analysts recommend STTK or AARD?

Summary

How does Aardvark Therapeutics compare to Ginkgo Bioworks?

Do analysts rate AARD or DNA?

Do insiders and institutionals believe in AARD or DNA?

Is AARD or DNA more profitable?

Which has more risk & volatility, AARD or DNA?

Does the media favor AARD or DNA?

Which has preferable valuation and earnings, AARD or DNA?

Summary

How does Aardvark Therapeutics compare to Eikon Therapeutics?

Is EIKN or AARD more profitable?

Which has higher valuation & earnings, EIKN or AARD?

Does the media favor EIKN or AARD?

Do analysts rate EIKN or AARD?

Summary

How does Aardvark Therapeutics compare to Contineum Therapeutics?

Does the media prefer CTNM or AARD?

Is CTNM or AARD more profitable?

Do analysts recommend CTNM or AARD?

Which has stronger earnings and valuation, CTNM or AARD?

Which has more volatility and risk, CTNM or AARD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools